Maxim Group analyst Jason McCarthy reiterated a Buy rating on Iterum Therapeutics today and set a price target of $5.00. The company’s shares closed yesterday at $0.67.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, SCYNEXIS, and Atossa Therapeutics. According to TipRanks, McCarthy has an average return of -17.7% and a 31.66% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iterum Therapeutics with a $5.00 average price target.
Based on Iterum Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.51 million. In comparison, last year the company had a GAAP net loss of $5 million
Read More on ITRM:
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/A%20Palantir%20sign%20displayed%20on%20an%20office%20building%20by%20Poetra_RH%20via%20Shutterstock.jpg)
